Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,830,868
  • Shares Outstanding, K 252,900
  • Annual Sales, $ 1,702 M
  • Annual Income, $ -112,050 K
  • 36-Month Beta 1.58
  • Price/Sales 21.34
  • Price/Cash Flow 1,022.26
  • Price/Book 20.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
136.50 +3.59%
on 12/07/17
151.75 -6.82%
on 11/15/17
-7.34 (-4.93%)
since 11/10/17
3-Month
136.50 +3.59%
on 12/07/17
158.04 -10.53%
on 10/18/17
-15.42 (-9.83%)
since 09/12/17
52-Week
71.46 +97.87%
on 12/22/16
167.85 -15.76%
on 07/25/17
+65.32 (+85.86%)
since 12/12/16

Most Recent Stories

More News
Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and B-Thalassemia

---Clinical Trial Application for CTX001 submitted in Europe to support initiation of Phase 1/2 clinical study in B-thalassemia in 2018-

CRSP : 18.06 (-1.90%)
VRTX : 140.82 (-0.61%)
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018

Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.

JNJ : 143.16 (+1.43%)
MRK : 56.98 (+1.14%)
VRTX : 140.82 (-0.61%)
BMRN : 87.21 (-1.02%)
INCY : 95.73 (-1.56%)
PFE : 36.59 (+1.05%)
ALXN : 113.77 (+1.67%)
Vertex Kalydeco Study Successful in Children Aged 1-2 Years

Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.

XOMA : 32.78 (-0.27%)
MYGN : 32.67 (+0.58%)
EBS : 45.30 (+2.67%)
VRTX : 140.82 (-0.61%)
Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO(R) (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years

---Potential to modify the course of CF in children as young as one year of age-

VRTX : 140.82 (-0.61%)
New Pharma ETF PILL : What Investors Need to Know

Inside the pros and cons of the pharma sector and chances of outperformance of the just-launched fund PILL.

UBIO : 32.75 (-1.36%)
PJP : 64.50 (+0.64%)
VRTX : 140.82 (-0.61%)
CURE : 47.98 (+0.97%)
LABU : 70.17 (-4.43%)
GILD : 75.39 (-0.65%)
PILL : 27.56 (+2.07%)
New Pharma ETF PILL : What Investors Need to Know

Inside the pros and cons of the pharma sector and chances of outperformance of the just-launched fund PILL.

UBIO : 32.75 (-1.36%)
PJP : 64.50 (+0.64%)
VRTX : 140.82 (-0.61%)
CURE : 47.98 (+0.97%)
LABU : 70.17 (-4.43%)
GILD : 75.39 (-0.65%)
PILL : 27.56 (+2.07%)
The Zacks Analyst Blog Highlights: Starbucks, NIKE, Manulife, Intuit and Vertex

The Zacks Analyst Blog Highlights: Starbucks, NIKE, Manulife, Intuit and Vertex

INTU : 156.05 (+0.24%)
SBUX : 59.14 (+0.12%)
VRTX : 140.82 (-0.61%)
NKE : 62.18 (+0.44%)
MFC : 20.81 (+0.14%)
Top Analyst Reports for Starbucks, NIKE & Manulife

Top Analyst Reports for Starbucks, NIKE & Manulife

SBUX : 59.14 (+0.12%)
INTU : 156.05 (+0.24%)
VRTX : 140.82 (-0.61%)
LRCX : 182.44 (-1.68%)
NKE : 62.18 (+0.44%)
MFC : 20.81 (+0.14%)
Galapagos' CF Candidate Shows Potential in Phase II Study

Galapagos' (GLPG) CFTR corrector candidate, GLPG2222, shows potential in a phase II study on CF patients.

SCMP : 16.40 (+0.92%)
VRTX : 140.82 (-0.61%)
ABBV : 95.74 (-0.76%)
GLPG : 85.81 (-4.12%)
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3

After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.

CELG : 109.16 (+1.07%)
VRTX : 140.82 (-0.61%)
ABBV : 95.74 (-0.76%)
GILD : 75.39 (-0.65%)
AMGN : 175.63 (-0.68%)
ALXN : 113.77 (+1.67%)
BIIB : 325.44 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Vertex Pharmaceuticals is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to their clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research...

See More

Key Turning Points

2nd Resistance Point 145.91
1st Resistance Point 143.79
Last Price 140.82
1st Support Level 139.68
2nd Support Level 137.69

See More

52-Week High 167.85
Last Price 140.82
Fibonacci 61.8% 131.03
Fibonacci 50% 119.66
Fibonacci 38.2% 108.28
52-Week Low 71.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.